| Objective: Through clinical observation and detection of WBC,N%,CRP content in peripheral blood and IL-6,SP,MUC5 AC,MUC5ACm RNA in induced sputum,this study evaluated the clinical efficacy of atomized inhaled tanreqine injection on patients with acute onset of chronic bronchitis,and discussed the effect and mechanism of this method.Methods: According to inclusion criteria to choose between September 2018 and September 2019 in heilongjiang province hospital emergency department nangang branch of hospitalized patients 65 cases,adopt the method of random grouping,according to the proportion of 1:1 divided the patients into treatment group(33 cases,the control group,32 cases in treatment group adopted in foundation treatment(according to the results of drug susceptibility to choose the appropriate antibiotics,spasmolysis and asthma)combined with atomization inhalation phlegm heat injection,control group with atomization inhalation in the treatment of foundation of ammonia bromine injection,using statistical software SPSS22.0 compared two groups of patients before treatment and after treatment of symptom score,quality of life score,WBC,N%,CRP,IL-6,SP,MUC5 AC in the sputum after induction,and MUC5 ACm RNA in the treatment group before and after treatment.RESULT:1.Baseline Comparison: There were 60 cases included in the statistical analysis,including 30 patients in the treatment group and 30 patients in the control group.After testing,there were no statistically significant differences between the two groups in age,sex and acute onset time(P>0.05).Before treatment,the scores of cough,sputum,sputum and other symptoms were(5.83±1.367)vs(5.77±1.569),(3.53±1.525)vs(4.03±1.520),(5.83±1.367)vs(5.77±1.569)in the control group and(72.77±18.66)vs(74.90±20.24)in the two groups,respectively.The differences were not statistically significantand comparable(P>0.05).2.Comparison of clinical efficacy of symptoms between the two groups: after treatment,comparison of clinical efficacy of cough symptoms between the two groups: the total effective rate was 100% in the treatment group(8 cases recovered,12 cases showed obvious effect and 10 cases effective),and the total effective rate was 83.3% in the control group(1 case recovered,11 cases showed obvious effect and 14 cases effective).Thedifference between the two groups was statistically significant(P < 0.05).Comparison of clinical efficacy of cough symptoms between the two groups: the total effective rate was90% in the treatment group with 18 cases cured,4 cases showed obvious effect and 5 cases effective;the total effective rate was 80% in the control group with 6 cases cured,6 cases showed obvious effect and 12 cases effective;the difference between the two groups was statistically significant(P<0.05).The total effective rate was 93.3% in the treatment group and 93.3% in the control group.The total effective rate was 93.3% in the control group.There was no statistically significant difference between the two groups(P>0.05).3.Comparison of cough visual simulation scores and cough remission time between the two groups: during 1 week of treatment,comparison of cough visual simulation scores between the two groups: comparison of daytime,nighttime and total scores on the first and third day after treatment showed no statistically significant difference(P>0.05);On the fifth day after treatment,there was no statistically significant difference between the two groups(P>0.05).The night score and total score of cough in the two groups were(2.37±1.13)vs(3.53±1.72),(5.10±2.50)vs(6.80±2.81),with statistically significant difference(P<0.05).Day score,night score and total score of cough were(1.67±1.30)vs(2.53±1.11),(1.37±1.03)vs(2.83±1.70),(3.03±2.09)vs(5.37±2.44)on the seventh day after treatment,and the differences were statistically significant(P<0.05).The remission time of cough was 1.93±1.08 days in the treatment group and 3.60±2.01 days in the control group,and the difference was significant(P<0.05).4.Leicester score: before treatment,there was no significant difference in leicester score between the two groups(P>0.05);Lecherst scores after treatment were significantly different from those before treatment(P<0.05).The reduction in the treatment group was better than that in the control group(120.30±8.69)vs(111.47±14.80)(P<0.05).5.Comparison of IL-6,SP,MUC5 AC m RNA expression between the two groups before and after treatment: before treatment,the difference of IL-6,SP,MUC5 AC m RNA expression between the two groups was not statistically significant(P>0.05).After treatment,the levels of MUC5 AC and IL-6 in both groups were lower than before treatment(P<0.05).Moreover,the reduction degree of the treatment group was significantly better than that of the control group,and the difference was significant(P<0.05).There was no statisticallysignificant difference in SP level between the two groups(P>0.05).MUC5 AC m RNA expression level in the treatment group was lower than that before treatment,and the difference was significant(P<0.05).6.Comparison of WBC,N% and CRP in peripheral blood between the two groups before and after treatment: before treatment,there was no statistically significant difference in WBC,N% and CRP levels between the two groups(P>0.05);After treatment,the reduction degree of N% and CRP in the treatment group was significantly better than that in the control group,and the difference was significant(P<0.05).There was no significant difference in WBC level between the two groups(P>0.05).7.During the whole study,30 cases were observed in each group,and 5 cases were shed.Reasons for falling off: 2 cases in the treatment group and 1 case in the control group had chest tightness during atomization inhalation,and atomization stopped and symptoms disappeared after drug withdrawal.One case in each group was withdrawn from observation due to complications of pneumonia.CONCLUSION:1.The treatment of acute attack of chronic bronchitis with atomized inhalation of Tanreqing injection can improve the symptoms of cough and phlegm and improve the quality of life.2.Neutrophils,C-reactive protein and IL-6 and SP in peripheral blood of patients with acute attack of chronic bronchitis(phlegm-heat type)can be reduced.3.Atomized inhalation of Tanreqing injection can reduce the content of MUC5 AC in the induced sputum and inhibit the expression of MUC5 ACm RNA in patients with acute attack of chronic bronchitis(phlegm-heat stagnation type).4.Atomized inhalation of Tanreqing injection can reduce airway inflammation in patients with acute attack of chronic bronchitis(phlegm-heat type)and improve airway mucus hypersecretion in patients with acute attack of chronic bronchitis,which is one of the reasons for rapid and effective results. |
PDF Full Text Request